IP Library Patent Application 10514563
Patent Application
App. No. 10/514,563

Powdery respiratory tonic composition

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/514,563
Abstract

The present invention relates to powdery inhalant compositions, each of which contains a steroidal anti-inflammatory drug, a carrier and water and has a water activity at 25° C. of from 0.35 to 0.75. Each powdery inhalant composition according to the present invention is high in the delivery rate of its steroidal anti-inflammatory drug to an inhalation target site from the nasal cavities or oral cavity, that is, to the alveoli, the bronchioles, the bronchial tubes or the airway, and allows the steroidal anti-inflammatory to exhibit its superb therapeutic effects.

Claims (9)

1 . A powdery inhalant composition comprising a steroidal anti-inflammatory drug, a carrier and water and having a water activity at 25° C. of from 0.35 to 0.75.

2 . A powdery inhalant composition according to claim 1 , wherein said steroidal anti-inflammatory drug is a compound represented by the following formula (1) or a salt thereof:

wherein R 1 represents a hydrogen atom, a halogen atom, a hydroxyl group or —OCOR 4 in which R 4 represents a linear or branched alkyl, cycloalkyl or aryl group which may be substituted by one or more halogen groups or cycloalkyl groups, R 2 represents a hydrogen atom, a lower alkanoyl group or a cycloalkanoyl group, R 3 represents a hydrogen atom or a methyl group, and X represents a hydrogen atom or a halogen atom.

3 . A powdery inhalant composition according to claim 2 , wherein in said formula (1), R 1 is a cyclohexanecarbonyloxy group, R 2 is a cyclopropanecarbonyl group, R 3 is a methyl group, and X is a fluorine atom.

4 . A powdery inhalant composition according to any one of claims 1 - 3 , wherein said carrier comprises one or more carriers selected from saccharides, sugar alcohols, amino acids and inorganic salts.

5 . A powdery inhalant composition according to any one of claims 1 - 4 , wherein said carrier has a particle size distribution containing 50% or more particles smaller than 50 μm in particle size.

6 . A powdery inhalant composition according to any one of claims 1 - 5 , wherein a weight ratio of said steroidal anti-inflammatory drug to said carrier is from 1:100 to 1:10.

7 . A powdery inhalant composition according to any one of claims 1 - 5 , which is an intraoral inhalant preparation or an intranasal inhalant preparation.

8 . A method of treatment of an inflammatory airway disease, which comprises intraoral inhalation or intranasal inhalation of a powdery composition as defined in claim 1.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2007
From: HISAMITSU MEDICAL CO., LTD.
To: NIPPON SHINYAKU CO., LTD.
Reel/Frame 018946/0409 →
CHANGE OF NAME Recorded May 24, 2005
From: BIOMEDIX CO., LTD.
To: HISAMITSU MEDICAL CO., LTD.
Reel/Frame 016263/0884 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2005
From: SSP CO., LTD.
To: BIOMEDIX CO., LTD.
Reel/Frame 016216/0253 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2005
From: MIYADAI, NOBUO; OKADA, MINORU; HORIE, TOSHIAKI
To: SSP CO., LTD.
Reel/Frame 015643/0618 →